Volume 7 Supplement 1
HPV monitoring in kidney transplanted patients
© Buonaguro et al; licensee BioMed Central Ltd. 2012
Published: 19 April 2012
Renal allograft recipients, as for HIV/AIDS patients, have a well-documented increased incidence of human papillomavirus (HPV)-related malignancies and preventive strategies should be specifically implemented. While in females the use of the Papanicolau test and HPV detection assay are used currently as a screening test for cervical cancer, no diagnostic procedures have been implemented to monitor HPV infection in males. The aim of this study was to test for HPV infection and to determine the spectrum of viral genotypes in urine samples of men with renal transplants.
Material and methods
The study included 103 patients who underwent kidney transplantation between 1999 and 2008. HPV sequences were detected by nested PCR, using the broad-spectrum consensus- primer pairs MY09/MY11 and the new MGP system, and characterized by nucleotide sequence analysis.
Prevalence of HPV genotypes in renal transplant patients
HPV positive, n (%)
Total single infections
Total multiple infections
The high prevalence of HPV 16 among renal allograft recipients suggests that an HPV-16-based preventive or therapeutic vaccine may be effective for prevention or treatment of HPV-related neoplasia in this group of immune compromised patients.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.